Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL. Materials and methods: Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018. Results: Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment. Conclusion: The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.
Abstract
Purpose: Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL. Materials and methods: Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018. Results: Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment. Conclusion: The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.
참고문헌 (28)
- Grommes C, "Primary CNS lymphoma", J Clin Oncol, 35, pp.2410~2418 (2017)
- Thiel E, "High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma(G-PCNSL-SG-1) : a phase 3, randomised, non-inferiority trial", Lancet Oncol, 11, pp.1036~1047 (2010)
- Hoang-Xuan K, "Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients : guidelines from the European Association for Neuro-Oncology", Lancet Oncol, 16, pp.e322~e332 (2015)
- Vater I, "The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing", Leukemia, 29, pp.677~685 (2015)
- Zhou Y, "Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes", Neoplasia, 20, pp.1059~1069 (2018)
- Jen J, "An overview on the isolation and analysis of circulating tumor DNA in plasma and serum", Ann N Y Acad Sci, 906, pp.8~12 (2000)
- Gerlinger M, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N Engl J Med, 366, pp.883~892 (2012)
- Weaver KD, "Methylated tumor-specific DNA as a plasma biomarker in patients with glioma", Cancer Invest, 24, pp.35~40 (2006)
- Liu BL, "Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas", Neuro Oncol, 12, pp.540~548 (2010)
- Best MG, "Liquid biopsies in patients with diffuse glioma", Acta Neuropathol, 129, pp.849~865 (2015)
- Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies", Sci Transl Med, 6, pp.224~ (2014)[DOI]
- Hickmann AK, "Molecular tumor analysis and liquid biopsy : a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas", BMC Cancer, 19, pp.192~ (2019)
- Rossi D, "Liquid biopsy in lymphoma", Haematologica, 104, pp.648~652 (2019)
- Hattori K, "Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma", Cancer Sci, 109, pp.225~230 (2018)
- Bobillo S, "Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas", Haematologica, 106, pp.513~521 (2021)
- Wang X, "Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma", Clin Transl Med, 11, pp.e236~ (2021)
- Abrey LE, "Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma", J Clin Oncol, 23, pp.5034~5043 (2005)
- Newman AM, "Integrated digital error suppression for improved detection of circulating tumor DNA", Nat Biotechnol, 34, pp.547~555 (2016)
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Li H, "A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data", Bioinformatics, 27, pp.2987~2993 (2011)
- Shin SH, "Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes", Leuk Lymphoma, 60, pp.2237~2246 (2019)
- Fontanilles M, "Somatic mutations detected in plasma cell-free DNA by targeted sequencing : assessment of liquid biopsy in primary central nervous system lymphoma", Blood, 126, pp.332~ (2015)
- Watanabe J, "Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma", Leuk Lymphoma, 60, pp.3587~3589 (2019)
- Asmar F, "Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma", Haematologica, 98, pp.1912~1920 (2013)
- Reddy A, "Genetic and functional drivers of diffuse large B cell lymphoma", Cell, 171, pp.481~494 (2017)
- Kubuki Y, "TET2 mutation in diffuse large B-cell lymphoma", J Clin Exp Hematop, 56, pp.145~149 (2017)
- Dominguez PM, "TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lmphomagenesis", Cancer Discov, 8, pp.1632~1653 (2018)
- Fontanilles M, "Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma", Oncotarget, 8, pp.48157~48168 (2017)